A Clinical Study to Investigate Collagen Matrix 10808 for Soft Tissue Volume Augmentation Around Single Implants
Launched by GEISTLICH PHARMA AG · Feb 2, 2015
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
The primary objective of this study is to assess the effectiveness of soft tissue volume augmentation procedures using the autogenous soft tissue graft or the Collagen Matrix 10808 to gain mucosal thickness. Second the safety of the two procedures will be investigated.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Implant placement at least 6 weeks and maximum 6 months prior enrolment
- • 2. Necessity of soft tissue augmentation in single tooth gap
- • 3. 2 teeth adjacent to each side of the defect have a mean BOP (Bleeding of probing) of \< 30%
- • 4. Basic periodontal examination (BPE \<2)
- • 5. 18 years or older
- • 6. Ability to comply with the study-related procedures such as exercising good oral hygiene and attending all follow-up procedures
- • 7. Ability to fully understand the nature of the proposed surgery and ability to sign the informed consent form
- Exclusion Criteria:
- • 1. Heavy smoker (\> 10 cigarettes per day)
- • 2. Probing depth greater than 4 mm
- • 3. Insulin dependent diabetes
- • 4. General contraindications for dental and/or surgical treatment
- • 5. History of malignancy, radiotherapy, or chemotherapy for malignancy within the past five years
- • 6. Women of child bearing age, not using a standard accepted method of birth control
- • 7. Pregnancy or breast feeding
- • 8. Previous and concurrent medication affecting mucosal healing in general (e.g. steroids, large doses of anti-inflammatory drugs)
- • 9. Disease affecting connective tissue metabolism (e.g. collagenases).
- • 10. Allergy to collagen
- • 11. Participation in a clinical trial within the last six months
About Geistlich Pharma Ag
Geistlich Pharma AG is a leading global company specializing in regenerative medicine and biomaterials, particularly within the fields of dental and orthopedic surgery. With a commitment to innovation and quality, Geistlich develops advanced solutions that support tissue regeneration and healing processes. The company’s extensive portfolio includes products designed for bone regeneration, soft tissue augmentation, and guided bone regeneration, all backed by comprehensive scientific research and clinical evidence. Through its dedication to improving patient outcomes and enhancing surgical techniques, Geistlich Pharma AG plays a pivotal role in advancing healthcare practices worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Patients applied
Trial Officials
Lorenz Uebersax, PhD
Study Director
Geistlich Pharma AG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials